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Sustained Chronic Obesity Results in Chronic 
Stretch, Diffuse Interstitial Fibrosis, Conduction 
Abnormalities, and Increased Vulnerability to AF 
In an animal study, 10 chronically obese sheep, 
compared with 10 age-matched controls, demonstrated 
greater total body fat, left atrial (LA) volume, LA pressure, 
and pulmonary artery pressures, reduced atrial conduction 
velocity with increased conduction heterogeneity, 
increased fractionated electrograms, decreased posterior 
LA voltage, and increased voltage heterogeneity (all 
p<0.001), with no change in the effective refractory period 
(ERP) or ERP heterogeneity. Obesity was associated with 
more episodes (p=0.02), prolongation (p=0.01), and 
greater cumulative duration (p=0.02) of atrial fibrillation 
(AF). Epicardial fat infiltrated the posterior LA in the 
obese group (p<0.001), consistent with reduced 
endocardial voltage in this region. Atrial fibrosis (p=0.03) 
and atrial transforming growth factor (TGF)-β1 protein (p= 
0.002) were increased in the obese group. The authors 
concluded that obesity results in global biatrial endocardial 
remodeling, and increased propensity for AF (Mahajan R 
et al, J Am Coll Cardiol 2015;66:1-11).   
An Increased Percentage of PVCs on 24-h Holter 
Monitor Confers a Decrease in LVEF, Increased 
Incident CHF, and Increased Mortality: PVCs might 
be an Important Cause of Occult or “Idiopathic” 
Cardiomyopathy and an Important Determinant of 
Incident CHF Among Those with Other Established 
CHF Risk Factors Among 1,139 Cardiovascular Health 
Study (CHS) participants, with a normal LVEF and no 
history of CHF, randomly assigned to 24-h Holter 
monitoring, those in the upper quartile vs the lowest 
quartile of PVC frequency had a 3-fold greater odds of a 
5-year decrease in LVEF (odds ratio - OR: 3.10; p= 0.005), 
a 48% increased risk of incident CHF (HR: 1.48; p= 0.02), 
and a 31% increased risk of death (HR: 1.31; p = 0.01) 
during a median follow-up of >13 years. The specificity 
for the 15-year risk of CHF exceeded 90% when PVCs 
included at least 0.7% of ventricular beats. The population-
level risk for incident CHF attributed to PVCs was 8.1%. 
The authors concluded that in a population-based sample, 
a higher frequency of PVCs was associated with a decrease 
in LVEF, an increase in incident CHF, and increased 
mortality (Dukes JW et al, J Am Coll Cardiol 2015;66:101-
109).   
Excessive Atrial Ectopy and Short Atrial Runs Confer 
an Increased Risk of Stroke Beyond Atrial Fibrillation 
(AF): Undiscovered Incident AF, Thrombogenic Atrial 
Disease or an Increased Vascular Risk Profile? 
15-year data from the Copenhagen Holter Study (678 
patients, ages 55-75 years, with no prior history of cardio-
vascular disease, stroke, or AF) showed that 99 (15%) 
individuals had excessive supraventricular ectopic activity 
(ESVEA), i.e. ≥30 premature atrial contractions (PACs)/h 
daily or any runs of ≥20 PACs. ESVEA was associated 
with ischemic stroke when censoring subjects at time of 
AF (hazard ratio -HR: 1.96) or when modeling AF as a 
time-varying exposure (HR: 2.0). Among subjects with 
ESVEA who developed a stroke, ~14% had diagnosed AF 
before their stroke. The incidence of stroke in subjects with 
ESVEA and a CHA2DS2-VASc score ≥2 was 2.4% per 
year, comparable to the risk observed in AF. The authors 
concluded that ESVEA may confer an increased risk of 
ischemic stroke beyond manifest AF. Stroke was more 
often the first clinical presentation, rather than AF (Larsen 
BS et al, J Am Coll Cardiol 2015;66:232–241).   
Trends in Acute Aortic Dissection (AAD) Over 17 Years: 
Patients with Type A AAD have been More Often Managed 
Surgically with Decreasing Mortality / Endovascular Repair 
is Increasingly Used at Referral Centers for Patients with 
Complicated Type B Dissection 
Over 17-years, Registry data from 4,428 patients (AAD 
type: A, n= 2,952; B, n= 1,476) indicated no change in the 
presenting complaints of severe or worst-ever pain for type 
A (93%) and type B AAD (94%), nor in the incidence of 
chest pain (83% & 71%, respectively). Use of computed 
tomography (CT) for diagnosis of type A increased from 
46% to 73% (p< 0.001), and surgical management from 
79% to 90% (p< 0.001). Endovascular management of type 
B increased from 7% to 31% (p< 0.001). Type A in-
hospital mortality decreased significantly (31% to 22%; p< 
0.001), as surgical mortality (25% to 18%; p=0.003). There 
was no significant trend in in-hospital mortality in type B 
(12% & 14%) (Pape LA et al, J Am Coll Cardiol 
2015;66:350–358).   
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Consensus & New Definition of Early RepolarizationJp 
(the Peak of an End-QRS Notch and/or the Onset of an 
End-QRS Slur as a Measure) should be >0.1 mv, while 
ST Elevation is not a Required Criterion 
According to a consensus paper, early repolarization is 
present if all of the following criteria are met: 1) An end-
QRS notch or slur on the downslope of a prominent R-
wave. The notch and the onset of a slur should lie entirely 
above the baseline. 2) Jp ≥0.1 mV in 2 or more contiguous 
ECG leads, excluding leads V1 to V3. 3) QRS duration 
<120 ms. ST-segment elevation in the absence of a slur or 
notch should not be reported as early repolarization. QRS 
duration should be measured using those leads that do not 
exhibit a notch or slur. Leads V1 to V3 have been excluded 
from the new definition of early repolarization to avoid 
confusion with the Brugada pattern, which is regarded by 
some as a form of early repolarization. Finally, they 
suggest that an upward-sloping ST-segment, followed by 
an upright T-wave in the presence of end-QRS notching or 
slurring, is benign, whereas early repolarization with a 
horizontal or downward-sloping ST-segment is 
potentially more serious. The authors conclude that in view 
of the relatively high prevalence of the early repolarization 
pattern without ST-segment elevation in apparently 
healthy subjects, in the absence of syncope or a strong 
family history of juvenile SCD, the finding of early 
repolarization does not merit further investigation, 
irrespective of ST-segment slope (Macfarlane PW et al, J 
Am Coll Cardiol 2015;66:470-477).   
RITA-3 Trial: The Advantage of Reduced Mortality of 
a Routine Invasive vs a Selective Invasive Strategy in 
Non–ST-Segment Elevation Acute Coronary 
Syndrome Seen at 5 Years Attenuated at 10 Years 
RITA-3 trial comparing outcomes of a routine early 
invasive strategy to those of a selective invasive strategy 
(for recurrent ischemia only) in patients with non–ST-
segment elevation acute coronary syndrome (NSTEACS) 
showed a 24% reduction of all-cause mortality of the 
routine invasive strategy at a median of 5 years. At 10-
years, among 1,810 patients with NSTEACS, there were 
no differences in mortality between the 2 groups. Risk of 
death varied markedly from 14.4 % in the low-risk group 
to 56.2% in the high-risk group. This mortality trend did 
not depend on the assigned treatment strategy (Henderson 
RA et al, J Am Coll Cardiol 2015;66:511-520).  
PROSE-ICD: Among Patients Undergoing Primary 
Prevention ICD Implantation, 40% Showed an 
Improved LVEF During Follow-Up, and in 25%, 
LVEF Improved to >35%  
Among 538 patients having an ICD for primary 
prevention of sudden cardiac death, over a mean follow-up 
of 4.9 years, LVEF decreased in 13%, improved in 40%, 
and was unchanged in 47% of the patients. Comparing 
patients with an improved LVEF with those with an 
unchanged LVEF, the hazard ratios were 0.33 for mortality 
and 0.29 for appropriate shock. During follow-up, 25% of 
patients showed an improvement in LVEF to >35% and 
their risk of appropriate shock decreased but was not 
eliminated (not enough to warrant deferring ICD generator 
replacement) (Zhang Y et al, J Am Coll Cardiol 
2015;66:524-531).   
ACTION Registry–GWTG: ~1/4 of Older Patients 
With AF who Undergo Coronary Stenting after Acute 
MI in the US are Discharged on DAPT plus an 
Anticoagulant (Triple Therapy) and Have Similar 
Rates of MACE but Significantly Greater Risk of 
Bleeding, Including Intracerebral Hemorrhage  
Among 4,959 patients ≥65 years of age with acute MI 
and AF who underwent coronary stenting, 27.6% (n= 
1,370) were discharged on triple therapy (dual antiplatelet 
therapy - DAPT plus warfarin). Relative to DAPT, patients 
on triple therapy had a similar risk of MACE (hazard ratio 
- HR: 0.99) but significantly greater risk of bleeding 
requiring hospitalization (HR: 1.61) and greater risk of 
intracranial hemorrhage (HR: 2.04) (Hess CN et al, J Am 
Coll Cardiol 2015;66:616-627).  
Like Hyponatremia, Hypochloremia in Patients 
Hospitalized for Acute Decompensated Heart Failure 
(ADHF) is Independently Associated With Long-Term 
Mortality  
Among 1,318 consecutive patients with chronic heart 
failure admitted for ADHF and also in an independent 
ADHF cohort (n= 876), admission serum chloride levels 
were independently and inversely associated with long-
term mortality (hazard ratio - HR per unit change: 0.94; 
p<0.001), and in multivariable analysis remained 
independently associated with mortality (HR: 0.93; p< 
0.001) in contrast to admission sodium levels, which were 
no longer significant (p > 0.05) (Grodin JL et al, J Am Coll 
Cardiol 2015;66:659-666).   
APPRAISE-2 Trial: in Patients with Acute Coronary 
Syndrome (ACS), no Benefit and Greater Bleeding 
with Apixaban Given Concomitantly with Aspirin or 
with the Combination of Aspirin plus Clopidogrel  
A total of 7,364 high-risk ACS patients treated with 
aspirin (n=1,202 or 16.3%) or aspirin plus clopidogrel (in 
= 5,814 or 79%) were randomized to apixaban 5 mg twice 
daily or placebo. No differential effect of apixaban vs 
placebo was observed for the composite endpoint 
(cardiovascular death, MI, and ischemic stroke) in patients 
taking aspirin (12.21 vs 13.21 per 100 patient-years; 
hazard ratio - HR: 0.91) or aspirin plus clopidogrel (13.22 
vs 14.24; HR: 0.95). Compared with placebo, apixaban 
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increased major bleeding in patients taking aspirin (1.48 vs 
0.25; HR: 6.62) and in patients taking aspirin plus 
clopidogrel (2.58 vs 1.02; HR: 2.44). Similar results were 
obtained and in patients treated with and without PCI. The 
authors concluded that post-ACS treatment with apixaban 
vs placebo showed no efficacy, but it increased bleeding 
regardless of concomitant therapy with aspirin alone or 
aspirin plus clopidogrel (Hess CN et al, J Am Coll Cardiol 
2015;66:777-787).   
IPAC Study: Most Women Presenting With Peri-
partum Cardiomyopathy (PPCM) Recover Myocardial 
Function Completely With Conventional Heart Failure 
Therapy During the First Year Post-Partum / Women 
With More Severe LV Dysfunction or Dilation at 
Presentation Have Less Chance of Full Recovery 
100 women with PPCM were followed through 1 year 
post-partum. Among them 30% were black, 65% white, 
5% other; mean age 30 ± 6 years; 88% were receiving beta-
blockers and 81% angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers. The LVEF at 
study entry was 0.35 ± 0.10, 0.51 ± 0.11 at 6 months, and 
0.53 ± 0.10 at 12 months. By 1 year, 13% had experienced 
major events or had persistent severe cardiomyopathy with 
an LVEF <0.35, and 72% achieved an LVEF ≥0.50. An 
initial LVEF <0.30, an LVEDD ≥6 cm, black race, and 
presentation after 6 weeks post-partum were associated 
with a lower LVEF at 12 months. No subjects with both a 
baseline LVEF <0.30 and an LVEDD ≥6 cm recovered by 
1 year, whereas 91% with both a baseline LVEF ≥0.30 and 
an LVEDD <6 cm recovered (p < 0.00001) (McNamara 
DM et al, J Am Coll Cardiol 2015;66:905-914).  
CARDIO-FIT Study: Increased Cardiorespiratory 
Fitness is Synergistic With Weight Loss as Part of the 
Management Strategy for Rhythm Control in 
Overweight and Obese Patients With AF  
Of 308 patients with atrial fibrillation (AF) and a body 
mass index ≥27 kg/m2 offered risk factor management and 
participation in a tailored exercise program, 95 patients 
had low, 134 adequate, and 79 high cardio-respiratory 
fitness at baseline. Over 49+19 months, total arrhythmia-
free survival rates was 17% in the low, 76% in the 
adequate, and 84% in the high cardiorespiratory fitness 
groups (p<0.001). On multivariable analysis, the low 
cardiorespiratory fitness (hazard ratio - HR: 5.94; p < 
0.001) and no weight loss group (HR: 3.64) remained an 
independent predictor of AF recurrence. Arrhythmia-free 
survival with and without rhythm control strategies was 
greatest in patients with high cardiorespiratory fitness (p < 
0.001). AF burden and symptom severity decreased 
significantly in the group with cardiorespiratory fitness 
gain ≥2 METs as compared to <2 METs group (p < 0.001). 
The authors concluded that cardiorespiratory fitness 
predicts arrhythmia recurrence in obese individuals with 
symptomatic AF. Improvement in cardiorespiratory fitness 
augments the beneficial effects of weight loss (Pathak RK 
et al, J Am Coll Cardiol 2015;66:985-996).   
PREVEND Study: Despite Considerable Progress in 
Management of Cardiovascular Disease, the Incidence 
of AF has not Decreased, and is Associated With 
Adverse Cardiovascular Outcomes, Including Heart 
Failure and Stroke / Obesity Has Emerged as an 
Additional Risk Factor for AF 
Among 8,265 Dutch participants over 9.7 ± 2.3 years of 
follow-up, 265 participants developed AF (overall AF 
incidence of 3.3 per 1,000 person-years). Advancing age, 
male gender, antihypertensive drug use, higher body mass 
index, previous myocardial infarction, and previous stroke 
were associated with AF. AF was associated with 
cardiovascular events (hazard ratio - HR: 2.24; p= 0.035), 
heart failure with either reduced or preserved ejection 
fraction (HR: 4.52; p< 0.001), and all-cause mortality (HR: 
3.02; p< 0.001) (Vermond RA et al, J Am Coll Cardiol 
2015;66:1000-1007).   
Successful Initial Experience of Transapical Mitral 
Valve Replacement (TMVR) With a Novel 
Transcatheter Mitral Valve  
The first 3 patients (mean age 71 ± 9 years, 2 men; EF 
25-30%) who had successful TMVR (Edwards FORTIS 
device) via a transapical approach in Canada, had 
improvement in functional status, in exercise capacity, and 
in quality of life. At 6-month follow-up, all 3 patients 
remain alive, without hospital readmission for heart failure 
and with NYHA functional class ≤II (Altisent OA et al, J 
Am Coll Cardiol 2015;66:1011-1019)  
Percutaneous Pericardiocentesis With Continuous 
Drainage for 3-5 Days is a Safe and Effective Strategy 
for Pericardial Effusion (PE) Management in Patients 
With Cancer, Even in Presence of Thrombocytopenia  
Of 1,645 cancer patients referred for pericardial 
effusion (PE), 212 (13%) underwent pericardiocentesis, 
which was 99% successful with no procedural deaths. Four 
patients had major procedure-related bleeding 
independently of platelet count. Patients with catheter 
drainage for 3-5 days had the lowest recurrence rate (10%). 
Median overall survival was 143 days; older age (i.e., >65 
years), lung cancer, platelet count<20,000/μl, and 
malignant pericardial fluid were independently associated 
with poor prognosis. Patients with lung cancer, but not 
those with breast cancer, with proven malignant effusions 
had a significantly shorter median 1-year survival 
compared with those with nonmalignant effusions (16% vs 
49%, respectively; p= 0.01) (El Haddad D et al, J Am Coll 
Cardiol 2015;66:1119-1128).   
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The Age Threshold (65 Years) Used in the CHA2DS2-
Vasc System for Initiating Oral Anticoagulants (OACs) 
May Be Lower (50 Years), at Least in Taiwanese Atrial 
Fibrillation (AF) PatientsAmong 186,570 non-
anticoagulated AF Taiwanese patients, the annual risk of 
ischemic stroke for males <65 years (CHA2DS2-VASc 
score 0; n=9,416) was 1.15% and females (score 1; 
n=6,390) 1.12%, and continuously increased from younger 
to older age groups, with an increment in stroke risk 
evident for patients >50 years of age. At a cutoff of 50 
years, patients (both males and females) could be further 
stratified into 2 subgroups with different stroke risks (>50 
years: 1.78%/year; vs<50 years: 0.53%/year). The authors 
concluded that for Taiwanese patients 50-64 years of age, 
the annual stroke risk was 1.78%, which may exceed the 
threshold for OAC use for stroke prevention, while this 
was only 0.53% for AF patients <50 years of age, a truly 
low-risk obviating the need for OACs (Chao T-F et al, J 
Am Coll Cardiol 2015;66:1339-1347).   
CHANCE Trial: The Early (90-Day) Benefit of 
Clopidogrel and Aspirin in Decreasing Stroke Risk is 
Maintained at 1 Year 
The CHANCE trial showed that treatment with 
clopidogrel and aspirin decreases the 90-day risk of stroke 
without increasing bleeding risk among 5170 patients 
randomly assigned within 24 hours after onset of minor 
stroke or high-risk transient ischemic attack to clopidogrel-
aspirin therapy or to aspirin-alone. At 1-year, stroke 
occurred in 275 (10.6%) patients in the clopidogrel-aspirin 
group, in comparison with 362 (14%) patients in the 
aspirin group (hazard ratio, 0.78; P=0.006). Moderate or 
severe bleeding occurred in 7 (0.3%) patients in the 
clopidogrel-aspirin group and in 9 (0.4%) patients in the 
aspirin group (P=NS) (Wang Y et al, Circulation 
2015;132:40-46).  
 
Review & Meta-Analysis: Direct Oral Anticoagulants 
(DOACs) Have Equal Efficacy to Vitamin K 
Antagonists (VKA) in Managing Thrombotic Risks in 
the Elderly With Atrial Fibrillation (AF), but Different 
Bleeding Patterns  
Review and meta-analysis of 11 randomized trials of 
direct oral anticoagulants (DOACs) (dabigatran, apixaban, 
rivaroxaban, and edoxaban) reporting data for the elderly 
(>75 years) for efficacy and bleeding outcomes in 
comparison with VKA during treatment for acute venous 
thromboembolism or stroke prevention in AF, indicated 
similar or superior to VKA efficacy in managing 
thrombotic risks for each DOAC. A nonsignificantly 
higher risk of major bleeding than with VKA was observed 
with dabigatran 150 mg (odds ratio-OR, 1.18) but not with 
the 110-mg dose. There were significantly higher 
gastrointestinal bleeding risks with dabigatran 150 mg (OR 
1.78) and dabigatran 110 mg (OR 1.40) and lower 
intracranial bleeding risks than VKA for dabigatran 150 
mg (OR 0.43) and dabigatran 110 mg (OR 0.36). A 
significantly lower major bleeding risk in comparison with 
VKA was observed for apixaban (OR 0.63), edoxaban 60 
mg (OR 0.81), and 30 mg (OR 0.46), whereas rivaroxaban 
showed similar risks (Sharma M et al, Circulation 
2015;132:194-204).   
Danish Cohort Study: Restarting Anticoagulant 
Treatment After Intracranial Hemorrhage in Patients 
With Atrial Fibrillation (AF) Confers Lower Risk of 
Recurrent Stroke & Mortality Than not Restarting 
Among 1752 patients with AF on oral anticoagulant 
treatment with incident intracranial hemorrhage, at 1 year 
of follow-up, the rate of ischemic stroke/systemic 
embolism and all-cause mortality (per 100 person-years) 
for patients treated with oral anticoagulants was 13.6 
(hazard ratio 0.55), in comparison with 27.3 for nontreated 
patients and 25.7 for patients receiving antiplatelet 
therapy. The rate of recurrent intracranial hemorrhage for 
patients treated with oral anticoagulants was 8, in 
comparison with 8.6 for nontreated patients and 5.3 for 
patients receiving antiplatelet therapy. The authors 
concluded that oral anticoagulant treatment was associated 
with a significant reduction in ischemic stroke/all-cause 
mortality rates, supporting oral anticoagulant treatment 
reintroduction after intracranial hemorrhage as feasible 
(Nielsen PB et al, Circulation 2015;132:517-525).  
Fibrosis of the Papillary Muscles and Inferobasal Left 
Ventricular Wall May be the Arrhythmic Substrate of 
Mitral Valve Prolapse (MVP) 
Cardiac pathology of 43 (7%) MVP patients out of 650 
young (≤40 years) adults with sudden cardiac death (SCD) 
(26 females; age 19–40 years, median 32 years) showed 
bileaflet involvement in 70%, left ventricular fibrosis at the 
level of papillary muscles in all, and inferobasal wall in 
88%. Among 12 cases with available ECG, 10 (83%) had 
inverted T waves on inferior leads, and all had right 
bundle-branch block (RBBB) ventricular arrhythmias 
(VAs). Living patients with MVP with (n=30) and without 
(control subjects; n=14) complex VAs underwent contrast-
enhanced cardiac magnetic resonance. Patients with either 
RBBB type or polymorphic complex VAs (22 females; age 
range, 28–43 years; median, 41 years), showed a bileaflet 
involvement in 70% of cases. Left ventricular late 
enhancement was identified by contrast-enhanced cardiac 
magnetic resonance in 93% of patients vs 14% of control 
subjects (P<0.001). The authors concluded that fibrosis of 
the papillary muscles and inferobasal left ventricular wall 
is the structural substrate for VAs origin, and that contrast-
enhanced cardiac magnetic resonance may help to identify 
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this concealed substrate (Basso C et al, Circulation 
2015;132:556-566).   
Extracranial Systemic Embolic Events (SEEs) 
Constitute 11.5% of Clinically Recognized Thrombo-
embolic Events in Patients with AF and are Associated 
with High Morbidity and Mortality 
A total of 221 extracranial systemic embolic events 
(SEEs) in 219 patients were reported among 37,973 
patients in 4 randomized clinical trials of anticoagulation 
in AF over 91,746 patient-years of follow-up. The SEE 
incidence was 0.24 of 100 and stroke incidence was 1.92 
of 100 patient-years. In comparison with patients with 
stroke, those with SEE were more often female (56% vs 
47%; P=0.01) and had comparable mean age (73.1±8.5 vs 
73.5±8.8 years; P=NS) and mean CHADS2 scores (2.4±1.3 
vs 2.5±1.2; P=0.33). SEEs more frequently involved the 
lower extremity (58%) than visceral-mesenteric (31%) or 
upper extremity (10%). Management comprised clinic 
assessment alone in 5%, hospitalization in 30%, 
endovascular or surgical intervention in 60%, and 
amputation in 5%. Within 30 days, 54% of patients 
recovered fully, 20% survived with deficits, and 25% died. 
Visceral-mesenteric SEE had higher mortality than lower- 
or upper-extremity SEE. The relative risk of death was 
4.33 after SEE vs 6.79 after stroke (Bekwelem W et al, 
Circulation 2015;132:796-803).   
REACH Registry: Severe 4-Year Impact of Diabetes 
Mellitus on Hospitalization for Heart Failure, 
Cardiovascular (CV) Events, and Death 
Of the 45,227 patients in the REACH registry having 
4-year follow-up, 43.6% (n=19,699) had diabetes (DM) at 
baseline. Overall risk and hazard ratio (HR) of CV death, 
nonfatal MI, or nonfatal stroke were greater in patients 
with DM (16.5% vs 13.1%; hazard ratio-HR, 1.27). There 
was also an increase in both CV death (8.9% vs 6%; HR, 
1.38) and overall death (14.3% vs 9.9%; HR, 1.40). DM 
was associated with a 33% greater risk of hospitalization 
for heart failure (9.4% vs 5.9%; odds ratio - OR, 1.33). In 
diabetics, heart failure at baseline was independently 
associated with CV death (HR, 2.45; P<0.001) and 
hospitalization for heart failure (OR, 4.72; P<0.001) 
(Cavender MA et al, Circulation 2015;132:923-931).   
Danish Registry: A Family History of Premature 
Cardiomyopathy Death is Associated With an Increase 
in Risk of Cardiomyopathy, Supporting Need for 
Screening of Relatives of Cardiomyopathy Patients 
In a cohort of 3.9 million persons born from 1950 to 
2008, 3890 cardiomyopathies were identified in 89 million 
person-years of follow-up. Premature cardiomyopathy 
deaths in first- and second-degree relatives were associated 
with 29- and 6-fold increases in the rate of 
cardiomyopathy, respectively. If the first-degree relative 
died aged <35 years, the rate of cardiomyopathy increased 
100-fold; given ≥2 premature deaths in first-degree 
relatives, the rate increased >400-fold, while a family 
history of premature death from other cardiac or 
noncardiac conditions increased the rate of 
cardiomyopathy only 3-fold (Ranthe MF et al, Circulation 
2015;132:1013-1019).  
Endovascular Repair, Compared With Open Repair, 
of Abdominal Aortic Aneurysm (AAA) Confers an 
Early Survival Advantage but this Gradually 
Decreases Over Time, while the Rate of Late Rupture 
is Higher After Endovascular than After Open Repair 
Among 39,966 matched pairs of patients with AAA 
who had undergone either open or endovascular repair, the 
overall perioperative mortality was 1.6% with 
endovascular vs 5.2% with open repair (P<0.001). Over 
time, perioperative mortality decreased by 0.8% among 
patients with endovascular repair (P=0.001) and by 0.6% 
in patients who underwent open repair (P=0.01). The rate 
of conversion from endovascular to open repair decreased 
from 2.2% in 2001 to 0.3% in 2008 (P<0.001). Survival 
was higher after endovascular vs open repair at the first 3 
years of follow-up, but similar afterwards. At 8 years, 
interventions for the aneurysm or its complications were 
more common after endovascular repair, whereas 
interventions for complications related to laparotomy were 
more common after open repair. Aneurysm rupture 
occurred in 5.4% of patients after endovascular repair vs 
1.4% of patients after open repair (P<0.001) 
(Schermerhorn ML et al, N Engl J Med 2015; 373:328-
338).   
Idarucizumab for Dabigatran Reversal 
A total of 90 patients received 5 g of IV idarucizumab 
because of serious bleeding from dabigatran (group A, 
n=51) or because they required an urgent procedure (group 
B, n=39), and among 68 patients with an elevated dilute 
thrombin time and 81 with an elevated ecarin clotting time 
at baseline, the median maximum percentage reversal was 
100%. Idarucizumab normalized the test results in 88-98% 
of patients within minutes. Concentrations of unbound 
dabigatran remained <20 ng/ml at 24 hours in 79% of 
patients. Among 35 patients in group A being assessed, 
hemostasis was restored at a median of 11.4 hours. Among 
36 patients in group B who underwent a procedure, normal 
intraoperative hemostasis was reported in 33, and 
abnormal hemostasis in 3 patients. One thrombotic event 
occurred within 3 days after idarucizumab in a patient in 
whom anticoagulants had not been reinitiated. The authors 
concluded that idarucizumab completely reversed the 
anticoagulant effect of dabigatran within minutes (Pollack 
CV et al, N Engl J Med 2015; 373:511-520).  
94 
 
 
BARI 2D Study: Abnormal Cardiac Troponin T is an 
Independent Predictor of Death from Cardiovascular 
Causes, MI, or Stroke in Diabetic Patients with Stable 
Ischemic Heart Disease, but does not Predict Benefit 
from Prompt Coronary Revascularization 
Of the 2285 diabetic patients with stable ischemic heart 
disease, 2277 (99.6%) had detectable (≥3 ng per liter) 
high-sensitivity troponin T and 897 (39.3%) had abnormal 
troponin T (≥14 ng per liter) at baseline. The 5-year rate of 
the composite end point (death from cardiovascular causes, 
MI, or stroke) was 27.1% among patients with abnormal 
troponin T at baseline, as compared with 12.9% among 
those with normal baseline troponin T. The hazard ratio 
(HR) for the composite end point among patients with 
abnormal troponin T was 1.85 (P<0.001). Among patients 
with abnormal troponin T, random assignment to prompt 
revascularization, as compared with medical therapy 
alone, did not result in a significant reduction in the rate of 
the composite end point (HR, 0.96) (Everett BM et al, N 
Engl J Med 2015; 373:610-620).  
 
BRIDGE Trial: for Patients With AF who Require 
Temporary Interruption of Warfarin for an Elective 
Operation or Invasive Procedure, a Strategy with no 
Bridging was Noninferior to Perioperative Bridging 
with Low-Molecular-Weight Heparin for Prevention of 
Arterial Thromboembolism and also Decreased the 
Risk of Major Bleeding  
After perioperative interruption of warfarin, 1884 
patients were randomly assigned to receive bridging 
anticoagulation with low-molecular-weight heparin (100 
IU/kg of dalteparin) (n=934) or matching placebo (n=950) 
administered subcutaneously twice daily, from 3 days 
before the procedure until 24 hours before the procedure 
and then for 5-10 days after the procedure. Warfarin was 
stopped 5 days before the procedure and was resumed 
within 24 hours later. The incidence of arterial 
thromboembolism at 30 days was 0.4% in the no-bridging 
group and 0.3% in the bridging group (P=0.01 for 
noninferiority). The incidence of major bleeding was 1.3% 
in the no-bridging group and 3.2% in the bridging group 
(relative risk, 0.41; P=0.005 for superiority) (Douketis JD 
et al, N Engl J Med 2015; 373:823-833).   
 
Takotsubo Registry: Takotsubo Cardiomyopathy 
Represents an Acute Heart Failure Syndrome With 
Substantial Morbidity and Mortality and Has a Higher 
Prevalence of Neurologic or Psychiatric Disorders than 
an Acute Coronary Syndrome  
Of 1750 patients with takotsubo cardiomyopathy, 
89.8% were women (mean age, 66.8 years). Emotional 
triggers were present in 27.7% and physical triggers in 
36%, while 28.5% of patients had no evident trigger. In 
patients with takotsubo, as compared with an acute 
coronary syndrome, rates of neurologic or psychiatric 
disorders were higher (55.8% vs 25.7%) and the mean left 
ventricular ejection fraction was much lower (40.7±11.2% 
vs 51.5±12.3%) (P<0.001). Rates of severe in-hospital 
complications including shock and death were similar in 
the two groups. Physical triggers, acute neurologic or 
psychiatric diseases, high troponin levels, and a low 
ejection fraction on admission were independent 
predictors for in-hospital complications. During long-term 
follow-up, the rate of major adverse cardiac and 
cerebrovascular events was 9.9% per patient-year, and the 
rate of death was 5.6% per patient-year (Templin C et al, 
N Engl J Med 2015; 373:929-938).  
 
MATRIX Trial: in Patients With an Acute Coronary 
Syndrome, Rates of Major Adverse Cardiovascular 
Events Were not Significantly Lower with Bivalirudin 
than with Unfractionated Heparin, nor was the 
Composite of Urgent Target-Vessel Revascularization, 
Stent Thrombosis, or Adverse Clinical Events with a 
Post-PCI Bivalirudin Infusion  
A total of 7213 patients with an acute coronary 
syndrome for whom PCI was anticipated were randomized 
to either bivalirudin or unfractionated heparin; patients in 
the bivalirudin group were then randomly assigned to 
receive or not a post-PCI bivalirudin infusion. The rate of 
major adverse cardiovascular events (death, MI, or stroke) 
was not significantly lower with bivalirudin (10.3%) than 
with heparin (10.9%) (relative risk, 0.94; P=NS), nor was 
the rate of net adverse clinical events (major bleeding or a 
major adverse cardiovascular event) (11.2% and 12.4%, 
respectively; relative risk, 0.89; P=NS). Post-PCI 
bivalirudin infusion, as compared with no infusion, did not 
significantly decrease the rate of urgent target-vessel 
revascularization, definite stent thrombosis, or net adverse 
clinical events (11% and 11.9%, respectively; relative risk, 
0.91; P=NS) (Valgimigli M et al, N Engl J Med 2015; 
373:997-1009).  
 
CIRCUS Trial: Cyclosporin did not Attenuate 
Reperfusion Injury / In Patients With Anterior STEMI 
Referred for Primary PCI, Cyclosporine did not Result 
in Better Clinical Outcomes and did not Prevent 
Adverse Left Ventricular Remodeling at 1 Year 
A total of 970 patients with an acute anterior ST-
segment elevation myocardial infarction (STEMI) 
undergoing percutaneous coronary intervention (PCI) 
within 12 hours after symptom onset, having complete 
occlusion of the culprit coronary artery, were randomized 
to a bolus injection of cyclosporine (2.5 mg/kg) (n=395) or 
matching placebo (n=396) before coronary recanalization. 
The rate of the primary outcome, i.e. composite of death 
from any cause, worsening of heart failure during the 
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initial hospitalization, rehospitalization for heart failure, or 
adverse left ventricular remodeling (increase of >15% in 
the left ventricular end-diastolic volume) at 1 year, was 
59% in the cyclosporine group and 58.1% in the control 
group (odds ratio, 1.04; P=NS). Cyclosporine did not 
reduce the incidence of the separate clinical components of 
the primary outcome or other events, including recurrent 
infarction, unstable angina, and stroke. Safety profile was 
similar in the two groups (Cung T-T et al, N Engl J Med 
2015; 373:1021-1031).  
 
LEADLESS II Study: Satisfactory Performance of the 
Leadless Pacemaker 
An active-fixation leadless cardiac pacemaker was 
successfully implanted in 504 (95.8%) of 526 patients who 
required permanent single-chamber ventricular pacing. 
The intention-to-treat primary efficacy end point (both an 
acceptable pacing threshold, i.e ≤2.0 V at 0.4 ms, and an 
acceptable sensing amplitude, i.e. R wave ≥5 mV) through 
6 months was met in 270 of the 300 patients in the primary 
cohort (90%, P=0.007), and the primary safety end point 
(freedom from device-related serious adverse events 
through 6 months) was met in 280 of the 300 patients 
(93.3%; P<0.001). At 6 months, device-related serious 
adverse events were observed in 6.7% of the patients; 
events included device dislodgement with percutaneous 
retrieval (in 1.7%), cardiac perforation (in 1.3%), and 
pacing-threshold elevation requiring percutaneous 
retrieval and device replacement (in 1.3%) (Reddy VY et 
al, N Engl J Med 2015; 373:1125-1135). 
 
3SITES Study: Complications of Central Venous 
Catheterization / Subclavian-Vein Catheterization was 
Associated with a Lower Risk of Bloodstream Infection 
and Symptomatic Thrombosis and a Higher Risk of 
Pneumothorax than Jugular-Vein or Femoral-Vein 
Catheterization  
A total of 3471 catheters were inserted in 3027 ICU 
patients. There were 8, 20, and 22 primary outcome events 
(catheter-related bloodstream infection and symptomatic 
deep-vein thrombosis) in the subclavian, jugular, and 
femoral groups, respectively (1.5, 3.6, and 4.6 per 1000 
catheter-days; P=0.02). In pairwise comparisons, the risk 
of the primary outcome was significantly higher in the 
femoral group than in the subclavian group (hazard ratio - 
HR, 3.5; P=0.003) and in the jugular group than in the 
subclavian group (HR, 2.1; P=0.04), whereas the risk in the 
femoral group was similar to that in the jugular group (HR, 
1.3; P=0.30). Pneumothorax requiring chest-tube insertion 
occurred in association with 13 (1.5%) of the subclavian-
vein insertions and 4 (0.5%) of the jugular-vein insertions 
(Parienti J-J et al, N Engl J Med 2015; 373:1220-1229).  
 
The Extent of Coronary Artery Calcification (CAC) 
Accurately Predicts 15-Year Mortality in a Large 
Cohort of Asymptomatic Patients  
Among 9715 asymptomatic patients, the coronary 
artery calcification (CAC) score, over median follow-up of 
14.6 years, was highly predictive of all-cause mortality 
(P<0.001). Overall 15-year mortality rates ranged from 3% 
to 28% for CAC scores from 0 to >1000 (P<0.001). The 
relative hazard for all-cause mortality ranged from 1.68 for 
a CAC score of 1-10 (P<0.001) to 6.26 for a score of >1000 
(P<0.001) (Shaw LJ et al, Ann Intern Med 2015;163:14-
21). 
 
Meta-Analysis: PCSK9 Monoclonal Antibody Therapy 
Seems to be a Safe and Effective Strategy for Patients 
with Dyslipidemia  
Meta-analysis of 24 randomized trials comprising 
10,159 patients indicated that, compared with no antibody, 
treatment with PCSK9 antibodies led to marked reductions 
in LDL cholesterol levels (mean difference, −47.49%; P< 
0.001) and other atherogenic lipid fractions, and it reduced 
all-cause mortality (odds ratio - OR, 0.45; P = 0.015) and 
cardiovascular mortality (OR, 0.50; P=0.084). The rate of 
MI was significantly reduced with PCSK9 antibodies (OR, 
0.49; P = 0.030), and increases in the serum creatine kinase 
level were reduced (OR, 0.72; P = 0.026). Serious adverse 
events did not increase with PCSK9 antibodies (Navarese 
ER et al, Ann Intern Med 2015;163:40-51). 
 
Meta-Analysis: Extended Dual-Antiplatelet Therapy 
(DAPT) is Associated with Approximately 8 Fewer 
Myocardial Infarctions per 1000 Treated Patients per 
Year but 6 More Major Bleeding Events than Shorter-
Duration DAPT  
 Analysis of 9 trials comprising 28,808 patients 
indicated that longer-duration DAPT decreased risk for 
myocardial infarction (risk ratio - RR, 0.73) and increased 
mortality (RR, 1.19). There was evidence of increased risk 
for major bleeding with DAPT (RR, 1.63) (Spencer FA et 
al, Ann Intern Med 2015;163:118-126).  
 
In Patients with Mild Heart Failure (NYHA Class II), 
LVEF <30%, QRS >120 ms, CRT-D Appears to be 
Cost-Effective Compared to ICD Alone when a 
Reduction in Mortality is Expected 
Use of cardiac resynchronization therapy-defibrillator 
(CRT-D) in patients aged >65 years with a left ventricular 
ejection fraction (LVEF) of <30%, QRS duration of >120 
ms, and NYHA class I or II symptoms, increased life 
expectancy (9.8 years vs 8.8 years), QALYs (8.6 vs 7.6 
years), and costs ($286,500 vs $228,600), yielding a cost 
per QALY gained of $61,700. The cost-effectiveness of 
CRT-D was most dependent on the degree of mortality 
96 
 
reduction, device cost, battery life and patient’s age (Woo 
CY et al, Ann Intern Med 2015;163:417-426).  
 
North American Study of Arrhythmogenic Right 
Ventricular Cardiomyopathy (ARVC): Competitive 
Sport was Associated with a Two-Fold Increased Risk 
of Ventricular Tachyarrhythmia (VTA)/Death and 
Earlier Presentation of Symptoms, When Compared 
With Inactive Patients, and to Patients who 
Participated in Recreational Sport  
Among probands diagnosed with ARVC (n = 108), 
category of sports participation, i.e. competitive (n = 41), 
recreational (n = 48), and inactive (n = 19) determined 
prognosis. Competitive sport was associated with a 
significantly higher risk of VTA/death when compared 
with both recreational sport (hazard ratio - HR = 1.99, P = 
0.007) and inactive patients (HR = 2.05, P = 0.030). No 
increased risk of VTA/death was associated with 
recreational sport when compared with patients who were 
inactive (HR = 1.03, P = 0.930). Symptoms developed at 
an earlier age in patients who participated in competitive 
sport (30 ± 12 years), when compared with patients who 
participated in recreational sport (38 ± 17 years) (P = 
0.015) and inactive patients (41 ± 11 years) (P = 0.002) 
(Ruwald A-C et al, Eur Heart J 2015; 36: 1735-1743).  
 
Rotterdam Study: Chronic Obstructive Pulmonary 
Disease (COPD) is Associated with an Increased Risk 
for Sudden Cardiac Death (SCD) / The Risk Especially 
Increases in Persons with Frequent Exacerbations 5 
Years After the Diagnosis of COPD 
Among 13,471 subjects aged >45 years with up to 24 
years of follow-up, 1615 having a diagnosis of COPD, 
there were 551 cases of SCD. COPD was associated with 
an increased risk of SCD (hazard ratio - HR, 1.34). The 
risk particularly increased in the period 5.48 years after the 
diagnosis of COPD (HR 2.12) and increased further to a > 
three-fold higher risk in COPD subjects with frequent 
exacerbations during this period (HR 3.58) (Lahousse L et 
al, Eur Heart J 2015;36:1754-1761). 
 
VENTURE-AF: in Patients Undergoing Catheter 
Ablation (CA) for Atrial Fibrillation (AF), the Use of 
Uninterrupted Oral Rivaroxaban was Feasible and 
Event Rates Were Similar to those for Uninterrupted 
Vitamin K Antagonist (VKA) Therapy  
A total of 248 non-valvular AF patients (mean age 59.5 
years, 71% male, 74% paroxysmal AF, CHA2DS2-VASc 
score of 1.6) were randomized to uninterrupted 
rivaroxaban (20 mg qd) or to an uninterrupted VKA prior 
to CA and for 4 weeks afterwards. The average total 
heparin dose used intra-procedurally was slightly higher 
and mean ACT level attained slightly lower in rivaroxaban 
and VKA arms, respectively. The incidence of major 
bleeding was low (0.4%; 1 major bleeding event). 
Thromboembolic events were also low (0.8%; 1 ischemic 
stroke and 1 vascular death). All events occurred in the 
VKA arm and all after CA (Cappato R et al, Eur Heart J 
2015;36:1805-1811). 
 
Review & Meta-Analysis: Digoxin is Associated with 
Increased Mortality in Patients Treated for Atrial 
Fibrillation (AF) or for Heart Failure (HF) / Negative 
Effects of Digoxin are Particularly Seen in the AF 
Population and Somewhat Less Unfavourable Effects 
in the HF Population 
Meta-analysis of 19 reports (9 with AF patients, 7 with 
HF patients, and 3 with both) comprising 326,426 patients, 
indicated that digoxin use was associated with an increased 
relative risk of all-cause mortality (hazard ratio - HR 1.21, 
P < 0.01). Compared with subjects not receiving the drug, 
digoxin was associated with a 29% increased mortality risk 
(HR 1.29) in the subgroup of publications comprising 
235,047 AF patients. Among 91,379 heart failure patients, 
digoxin-associated mortality risk increased by 14% (HR 
1.14). The authors concluded that digoxin use is associated 
with an increased mortality risk, particularly among 
patients suffering from AF (Vamos M et al, Eur Heart J 
2015; 36: 1831-1838).  
 
PARADIGM-HF trial: Mode of Death / Treatment 
With Valsartan/Sacubitril or LCZ696 (Entresto), an 
Angiotensin Receptor-Neprilysin Inhibitor (ARNi), 
Compared With Enalapril in Chronic Heart Failure 
Patients Reduced Cardiovascular (CV) Death 
Primarily by Reducing Both Death Due to Worsening 
Heart Failure and Sudden Cardiac Death (SCD) 
Over a median of 27 months, among 8399 patients with 
chronic heart failure, NYHA class II–IV, and left 
ventricular ejection fraction ≤40%, the majority of deaths 
were cardiovascular (CV) (80.9%), and the risk of CV 
death was significantly reduced by treatment with ARNi 
(hazard ratio - HR 0.80, P < 0.001). Among CV deaths, 
both SCD (HR 0.80, P = 0.008) and death due to worsening 
heart failure (HR 0.79, P = 0.034) were reduced by 
treatment with ARNi compared with enalapril. Deaths 
attributed to other CV causes, including MI and stroke, 
were infrequent and distributed evenly between treatment 
groups, as were non-CV deaths (Desai AS et al, Eur Heart 
J 2015; 36: 1990-1997).  
 
Dutch Registry: Secundum Atrial Septal Defect (ASD) 
is Associated with Reduced Survival in Adult Men 
 In a total of 2207 adult patients (mean age 44.8 years, 
33% male), 102 deaths occurred during a cumulative 
follow-up of 13,584 patient-years. Median survival was 
79.7 years for men and 85.6 years for women with ASD. 
Compared with the age- and gender-matched general 
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population, survival was lower for male, but not for female 
patients (P = 0.015 and 0.766, respectively). Men had a 
higher risk of conduction disturbances (odds ratio - OR = 
1.63) supraventricular dysrhythmias (OR = 1.41), cerebro-
vascular thromboembolic events (OR = 1.53), and heart 
failure (OR = 1.91) (Kuijpers JM et al, Eur Heart J 2015; 
36: 2079-2086).  
 
EMPHASIS-HF Trial: Post Hoc Analysis Indicates 
that Eplerenone is Safe, Improves Survival, and May 
Prevent Re-Admission When Initiated Soon After a 
Hospitalization for HF or Acute Coronary Syndromes 
in Patients With Systolic HF and Mild Symptoms 
Post hoc analysis in 2338 patients (NYHA class II / left 
ventricular ejection fraction ≤35%) randomized to 
eplerenone within 180 days of a cardiovascular 
hospitalization (CVH) indicated that most of the CVHs at 
a median of 42 days were for heart failure (HF) (N = 1496, 
64%), acute coronary syndromes (N = 390, 16.7%), and 
arrhythmias (N = 197, 7.2%). The relative rate reductions 
in CV death/CVH, and all-cause mortality were similar 
whether treatment was initiated <42 or 42+ days after 
qualifying CVH. Absolute rate reductions were −5.61 
events per 100 patient × years in the <42 days group and 
−3.58 in the 42+ days group. The adverse effects of 
eplerenone were also unaffected by the time from the 
qualifying CVH (Girerd N et al, Eur Heart J 2015; 36: 
2310-2317). 
 
PADIS-PE Trial: Among Patients With Pulmonary 
Embolism Receiving 6 Months of Anticoagulant, 
Extended Treatment to 18 Months Reduced the 
Composite Outcome of Recurrent Venous Thrombosis 
and Major Bleeding Compared With Placebo, But the 
Benefit was Lost after Stopping Anticoagulation  
Among 371 adult patients who had experienced a first 
episode of symptomatic pulmonary embolism and had 
been treated initially for 6 months with a vitamin K 
antagonist, in those randomized to extended therapy or not, 
the primary outcome (recurrent venous thromboembolism 
or major bleeding at 18 months) occurred in 6 of 184 
patients (3.3%) in the warfarin group and in 25 of 187 
(13.5%) in the placebo group (hazard ratio - HR, 0.22; 
P =0 .001). Recurrent venous thromboembolism occurred 
in 3 patients in the warfarin group and 25 patients in the 
placebo group (HR, 0.15); major bleeding in 4 patients in 
the warfarin group and in 1 patient in the placebo group 
(HR, 3.96). Over 42 months, the composite outcome 
occurred in 33 patients (20.8%) in the warfarin group and 
in 42 (24.0%) in the placebo group (HR, 0.75). Rates of 
recurrent venous thromboembolism, major bleeding, and 
unrelated death did not differ between groups (Couturaud 
F et al, JAMA 2015;314:31-40). 
 
AMETHYST-DN Trial: in Patients with Hyperkalemia 
and Diabetic Kidney Disease, Patiromer, a Potassium-
Binding Polymer, in Doses of 4.2-16.8 g bid Resulted in 
Significant Decreases in Serum Potassium Level After 
4 Weeks of Treatment, Lasting Through 52 Weeks 
In 306 outpatients with type 2 diabetes (glomerular 
filtration rate, 15 to <60 mL/min/1.73 m2 and serum 
potassium >5.0 mEq/L), all receiving RAAS inhibitors, 
randomized to patiromer, the least squares mean reduction 
from baseline in serum potassium level at week 4 or time 
of first dose titration in patients with mild hyperkalemia 
was 0.35 mEq/L for the 4.2 g bid starting-dose group, 0.51 
mEq/L for the 8.4 g bid starting-dose group, and 0.55 
mEq/L for the 12.6 g bid starting-dose group. In those with 
moderate hyperkalemia, the reduction was 0.87 mEq/L for 
the 8.4 g bid starting-dose group, 0.97 mEq/L for the 12.6 
g bid starting-dose group, and 0.92 mEq/L for the 16.8 g 
bid starting-dose group (P <0 .001). From week 4 through 
week 52, significant mean decreases in serum potassium 
levels were observed at each monthly point in patients with 
mild and moderate hyperkalemia. Adverse events 
comprised hypomagnesemia (7.2%), constipation (6.3%), 
and hypokalemia (<3.5 mEq/L) (5.6%) (Bakris GL et al, 
JAMA 2015;314:151-161).  
 
Association Between Inadequate Blood Pressure 
Control and Increased Risk of Recurrent Intracerebral 
Hemorrhage (ICH) 
Among 1145 of 2197 consecutive patients with ICH 
surviving at least 90 days and followed up for a median of 
36.8 months, there were 102 recurrent ICH events among 
505 survivors of lobar ICH and 44 recurrent ICH events 
among 640 survivors of nonlobar ICH. During follow-up 
adequate BP control was achieved on at least 1 
measurement by 625 patients (54.6%) and consistently by 
495 patients (43.2%). The event rate for lobar ICH was 84 
per 1000 person-years among patients with inadequate BP 
control compared with 49 per 1000 person-years among 
patients with adequate BP control. For nonlobar ICH the 
event rate was 52 per 1000 person-years with inadequate 
BP control compared with 27 per 1000 person-years for 
patients with adequate BP control. Inadequate BP control 
was associated with higher risk of recurrence of both lobar 
ICH (hazard ratio - HR, 3.53) and nonlobar ICH (HR, 
4.23). Systolic BP during follow-up was associated with 
increased risk of both lobar ICH recurrence (HR, 1.33 per 
10-mm Hg increase) and nonlobar ICH recurrence (HR, 
1.54). Diastolic BP was associated with increased risk of 
nonlobar ICH recurrence (HR, 1.21 per 10-mm Hg 
increase) but not with lobar ICH recurrence (HR, 1.36) 
(Biffi A et al, JAMA 2015;314:904-912).  
 
Meta-Analysis for Treatment of In-Stent Restenosis 
(ISR)/ Two strategies should be considered: PCI with 
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Everolimus Eluting Stents Because of the Better 
Angiographic and Clinical Results than with the Other 
Treatment Strategies, and Drug-Coated Balloons 
Because of their Ability to Provide Favourable Results 
Without Adding a New Stent Layer  
Meta-analysis of 27 trials comprising 5923 patients 
with in-stent restenosis indicated that PCI with 
everolimus-eluting stents was the most effective treatment 
for percent diameter stenosis, with a difference of −9% vs 
drug-coated balloons (DCB), −9.4% vs sirolimus-eluting 
stents, −10.2% vs paclitaxel-eluting stents, −19.2% vs 
vascular brachytherapy, −23.4% vs bare metal stents, 
−24.2% vs balloon angioplasty, and −31.8% vs rotablation. 
DCB were ranked as the second most effective treatment, 
but without significant differences from sirolimus-eluting 
(–0.2%) or paclitaxel-eluting (–1.2%) stents (Siontis GC et 
al, Lancet 2015;386 (9994):655–664). 
 
DANAMI-3—PRIMULTI Trial: in Patients with 
STEMI and Multivessel Disease, Complete 
Revascularization Guided by FFR Measurements 
During the Index Admission Reduces the Risk of 
Future Events by Reducing Repeat Revascularizations  
 
After successful percutaneous coronary intervention 
(PCI) of the infarct-related artery, patients with STEMI 
(n=627) were randomly allocated either no further invasive 
treatment (n-313) or complete fractional flow reserve 
(FFR)-guided revascularization (n=314) before discharge. 
Over a median of 27 months, events comprising the 
primary endpoint (all-cause mortality, non-fatal 
reinfarction, and ischemia-driven revascularization of 
lesions in non-infarct-related arteries) were recorded in 68 
(22%) patients who had PCI of the infarct-related artery 
only and in 40 (13%) patients who had complete 
revascularization (hazard ratio 0.56; p=0.004) (Engstrøm 
T et al, Lancet 2015; 386(9994):665–671). 
 
ADVICE Study: Adenosine Testing to Identify and 
Target Dormant Pulmonary Vein Conduction During 
Catheter Ablation of Atrial Fibrillation is a Safe and 
Effective Strategy to Improve Arrhythmia-Free 
Survival in Patients With Paroxysmal Atrial 
Fibrillation 
Adenosine unmasked dormant pulmonary vein 
conduction in 284 (53%) of 534 patients. 102 (69.4%) of 
147 patients with additional adenosine-guided ablation 
were free from recurrence compared with 58 (42.3%) of 
137 patients with no further ablation, corresponding to an 
absolute risk reduction of 27.1% (p<0.0001) and a hazard 
ratio of 0.44 (p<0.0001). Of 115 patients without dormant 
pulmonary vein conduction, 64 (55.7%) remained free 
from recurrences (p=0.0191). Serious adverse events were 
similar in each group. One death (massive stroke) was 
deemed probably related to ablation in a patient included 
in the registry (Macle L et al, Lancet 2015; 386(9994): 
672–679).  
 
Important Review and Other Articles  
Non-compaction of the left ventricle (Hussein A et al, 
J Am Coll Cardiol 2015;66:578-585), Duration of dual 
antiplatelet therapy (Montalescot G et al, J Am Coll 
Cardiol 2015;66:832-847), orthostatic hypotension (Ricci 
F et al, J Am Coll Cardiol 2015;66:848-860), Cardiac 
fibrosis in atrial fibrillation (Dzeshka MS et al, J Am Coll 
Cardiol 2015;66:943-959), Cardiovascular toxicities 
associated with kinase inhibitors employed in cancer 
therapies (Li W et al, J Am Coll Cardiol 2015;66:1160-
1178), Leadless pacemakers (Miller MA et al, J Am Coll 
Cardiol 2015;66:1179-1189), Bridging anticoagulation 
(Rechenmacher SJ & Fang JC, J Am Coll Cardiol 
2015;66:1392-1403), 2015 ACC/HRS/SCAI left atrial 
appendage occlusion device societal overview (Masoudi 
FA et al, J Am Coll Cardiol 2015;66:1497-1513), Atrial 
myopathy underlying atrial fibrillation (Goldberger JJ et 
al, Circulation. 2015;132:278-291), International Task 
Force Consensus Statement on Treatment of 
Arrhythmogenic Right Ventricular Cardiomyopathy/ 
Dysplasia (Corrado D et al, Circulation 2015;132:441-
453), AHA/ADA Update on Prevention of Cardiovascular 
Disease in Adults With Type 2 Diabetes Mellitus (Fox CS 
et al, Circulation 2015;132:691-718), Drug therapy for 
heart valve diseases (Bore JS & Sharma A, Circulation 
2015;132:1038-1045), Heparin-induced 
thrombocytopenia (Greinacher A, N Engl J Med 2015; 
373:252-261), Ischemic limb gangrene with pulses 
(Warkentin TE, N Engl J Med 2015; 373:642-655), Guide 
for monitoring patients receiving direct oral anticoagulants 
for stroke prevention in atrial Fibrillation (Gladstone DJ et 
al, Ann Intern Med 2015;163:382-385), Diabetic 
cardiomyopathy (Seferović PM & Paulus WJ, Eur Heart J 
2015; 36: 1718-1727), Electromagnetic interference in 
cardiac implants (Napp A et al, Eur Heart J 2015; 36: 
1798-1804), Recommendations on pre-hospital and early 
hospital management of acute heart failure (Mebazaa A et 
al, Eur Heart J 2015; 36: 1958-1966), Impact of 
antidiabetic agents on cardiovascular disease (Ferrannini E 
et al, Eur Heart J 2015; 36: 2288-2296), Atrial flutter (Bun 
S-S et al, Eur Heart J 2015; 36: 2356-2363), PCSK9 
inhibitors (Shimada YJ et al, Eur Heart J 2015; 36: 2415-
2424), Treatment of atrial fibrillation (Prystowsky EN et 
al, JAMA 2015; 314:278-288), Diabetes advances in 
diagnosis and treatment (Natham DM, JAMA 2015; 
314:1052-1062), Hypertension (Poulter NR et al, Lancet 
2015; 386(9995): 801–812), Non-compaction 
cardiomyopathy (Towbin JA et al, Lancet 2015; 
386(9995):813–825).   
